Ocular Therapeutix, Inc. OCUL
At closeNov 10, 2026, 4:27 PM EST
After hours · Nov 10, 4:27 PM ET
- YTD
- -45.55%
- 1 year
- -38.97%
- Market cap
- 1.45B
- Revenue (ttm)
- 50.38M
- EPS (ttm)
- -1.44
- Shares out
- 220.02M
- Forward P/E
- -4.14
- YTD return
- -45.55%
- 1-year return
- -38.97%
- Volume
- 2.44M
- Avg volume
- 3.12M
- Open
- 6.85
- Previous close
- 6.85
- Day's range
- 6.60 – 6.87
- 52-week range
- 6.00 – 16.44
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 25.45 (+285.1%)
- Earnings date
- Feb 4, 2027
5D -0.46 (-6.51%)
Key statistics
- Enterprise value
- 1.06B
- PEG ratio
- 0.00
- Price / sales
- 28.87
- Price / book
- 3.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -11.50%
- Free cash flow
- -159.98M
- Total cash
- 530.61M
- Total debt
- 80.01M
- Return on equity
- -93.48%
- Short % of float
- 15.43%
- 50-day average
- 8.33
- 200-day average
- 8.99
Analyst view
Consensus: strong buy
- Target (low)
- 14.00
- Target (mean)
- 25.45
- Target (high)
- 34.00
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate -0.40776.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | -0.37 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.36348 | -0.42 | -0.06 | -15.55% |
| Aug 3, 2026 | Jun 30, 2026 | -0.39545 | -0.35 | +0.05 | +11.49% |
| May 5, 2026 | Mar 31, 2026 | -0.32 | -0.41 | -0.09 | -28.12% |
| Feb 5, 2026 | Dec 31, 2025 | -0.33 | -0.29 | +0.04 | +12.12% |
| Nov 4, 2025 | Sep 30, 2025 | -0.39 | -0.37 | +0.02 | +5.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 19, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 2, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 29, 2026 | Needham | reit | Buy | Buy |
| Sep 16, 2026 | Chardan Capital | main | Buy | Buy |
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ocutx.com
News
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $28 
Ocular Therapeutix Q3 2026 Earnings Call Transcript 
Ocular Therapeutix Q3 EPS $(0.42) Misses $(0.36) Estimate, Sales $12.874M Miss $14.339M Estimate 
Critical Analysis: Lyra Therapeutics (OTCMKTS:LYRA) and Ocular Therapeutix (NASDAQ:OCUL) 
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target 
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14 
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter - Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target - Ocular Therapeutix Announces Completion Of Pre-NDA Meeting With FDA For Investigational Product Candidate AXPAXLI For Treatment Of Wet Age-Related Macular Degeneration
Your note
Sign in to keep a note on OCUL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERMAN TODD | Officer | Sale | Oct 7, 2026 | 140,484 |
| DUGEL PRAVIN U | Chief Executive Officer | Stock Gift | Aug 24, 2026 | 0 |
| HEIER JEFFREY S. | Officer | Sale | Oct 1, 2026 | 307,457 |
| KAISER PETER KAZUO | Officer | Sale | Oct 1, 2026 | 254,388 |
| LINDSTROM RICHARD L | Director | Stock Award(Grant) | Jun 9, 2026 | 260,933 |
| MEYERS STEVE LAWRENCE | Officer | Stock Award(Grant) | Jan 1, 2026 | 217,628 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.96% | 32,844,043 | 217.10M | Jun 29, 2026 |
| Deep Track Capital, Lp | 8.96% | 19,686,282 | 130.13M | Jun 29, 2026 |
| Blackrock Inc. | 8.82% | 19,376,555 | 128.08M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.71% | 12,540,000 | 82.89M | Jun 29, 2026 |
| Summer Road LLC | 5.68% | 12,463,296 | 82.38M | Sep 29, 2026 |
| Venrock Adviser, LLC | 4.71% | 10,346,926 | 68.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.46% | 9,804,363 | 64.81M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 6,616,995 | 43.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.53% | 5,562,722 | 36.77M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.25% | 2,751,674 | 18.19M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.12% | 2,461,078 | 16.27M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.03% | 2,261,254 | 14.95M | Aug 30, 2026 |